Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination
Bibliographic record
Abstract
Backgrounds: Targeted therapies (such as Ibrutinib and Venetoclax) have improved Mantle Cell Lymphoma (MCL) patients’ outcomes. OAsIs trial has evaluated the efficacy and toxicity of the Ibrutinib Obinutuzumab plus venetoclax combination in both R/R and untreated MCL patients (NCT02558816, Le Gouill et al. Blood 2021). In the present work, we updated the outcome of patients enrolled in OASIS trial. Methods: The OASIS trial was a 3 arms multicenter prospective phase 1/2 trial. Arm A (n = 9) enrolled R/R patients who were treated with Obinutuzumab (Obi, 1000 mg) and Ibrutinib (Ibru, 560 mg). Patients in Arm B (R/R; n = 24) and C (newly diagnosed MCL; n = 15) were treated with Obi+Ibru+Venetoclax (Ven, 400 mg). Patients’ characteristics have been described in the original manuscript. Results: In cohorts A (n = 9) and B (n = 24), overall response rates were 89% and 71%, respectively. Median Follow-ups were 71.6 and 48m, the 4-y PFS were 67% and 50%, respectively. No safety signals appeared during long term FU. Patients who progressed were treated with Bendamustine-containing regimen (6 out of 10) and one patient received Odronextamab and anti-CD22xCD3 bispecific antibodies. For Cohort C (n = 15), the median follow-up was 46m (36, 49m). Median PFS and DOR were not reached, the estimated 48m-PFS and 36m-DOR were 80% (Figure 1A). Two patients prematurely discontinued, one early PD (after 4m) and one for Adverse Event (neuropathy after 9m). The early PD patient harbored no adverse event, especially no TP53 alteration. One patient with TP53 mutation is still experiencing long-term disease control. One patient experienced atrial fibrillation and one patient had acute cardiac failure. Regarding infections, one patient died of a progressive multifocal leukoencephalopathy after the completion of treatment. Two patients prematurely discontinued the treatment, one patient had a PD at C4 and has subsequently been treated with R-CHOP, one patient relapsed after treatment completion and has been treated with Glofitamab. In all, 2 patients progressed and 1 died in arm C (PML), hence, the 4-y OS is estimated to be 93% (Figure 1B). Encore Abstract - previously submitted to EHA 2023 The research was funded by: Roche SAS supplied obinutuzumab, Janssen-Cilag supplied ibrutinib and AbbVie supplied venetoclax. Roche SAS, Janssen-Cilag and AbbVie funded the trial Keywords: aggressive B-cell non-Hodgkin lymphoma, combination therapies, targeting the tumor microenvironment Conflicts of interests pertinent to the abstract. S. Rule Employment or leadership position: AstraZeneca
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".